Antifungal consumption, indications and selection of antifungal drugs in paediatric tertiary hospitals in Turkey: Results from the first national point prevalence survey

Simple item page
dc.contributor.authorÇağlar İ.
dc.contributor.authorDevrim İ.
dc.contributor.authorÖzdemir H.
dc.contributor.authorŞahbudak Z.
dc.contributor.authorSönmez G.
dc.contributor.authorBuyukcam A.
dc.contributor.authorGulhan B.
dc.contributor.authorKara A.
dc.contributor.authorAygun D.F.
dc.contributor.authorBayram N.
dc.contributor.authorCelebi S.
dc.contributor.authorÇetin B.
dc.contributor.authorNepesov M.İ.
dc.contributor.authorYilmaz A.T.
dc.contributor.authorKepenekli E.
dc.contributor.authorÇiftdogan D.Y.
dc.contributor.authorAcar M.K.
dc.contributor.authorYayla B.C.
dc.contributor.authorOkumuş C.
dc.contributor.authorEcevit Z.
dc.contributor.authorHatipoglu N.
dc.contributor.authorKuyucu N.
dc.contributor.authorKosker M.
dc.contributor.authorSen S.
dc.contributor.authorKarbuz A.
dc.contributor.authorSutcu M.
dc.contributor.authorDuramaz B.B.
dc.contributor.authorÖzen M.
dc.contributor.authorÇiftçi E.
dc.contributor.authorAlabaz D.
dc.contributor.authorKurugol Z.
dc.contributor.authorKara A.
dc.contributor.authorKanik S.
dc.contributor.authorKilic O.
dc.contributor.authorOncel S.
dc.contributor.authorSomer A.
dc.contributor.authorTapisiz A.
dc.contributor.authorBelet N.
dc.contributor.authorAkcan Ö.M.
dc.contributor.authorTürel Ö.
dc.contributor.authorOzkaya A.
dc.contributor.authorTezer H.
dc.contributor.authorCengiz A.B.
dc.contributor.authorİnce E.
dc.contributor.authorCamcioglu Y.
dc.contributor.authorKocabas E.
dc.contributor.authorArisoy E.S.
dc.contributor.authorSalman N.
dc.date.accessioned2024-07-22T08:09:26Z
dc.date.available2024-07-22T08:09:26Z
dc.date.issued2018
dc.description.abstractObjectives: The aim of this point prevalence survey was to evaluate the consumption, indications and strategies of antifungal therapy in the paediatric population in Turkey. Methods: A point prevalence study was performed at 25 hospitals. In addition to general data on paediatric units of the institutes, the generic name and indication of antifungal drugs, the presence of fungal isolation and susceptibility patterns, and the presence of galactomannan test and high-resolution computed tomography (HRCT) results were reviewed. Results: A total of 3338 hospitalised patients were evaluated. The number of antifungal drugs prescribed was 314 in 301 patients (9.0%). Antifungal drugs were mostly prescribed in paediatric haematology and oncology (PHO) units (35.2%), followed by neonatal ICUs (NICUs) (19.6%), paediatric services (18.3%), paediatric ICUs (PICUs) (14.6%) and haematopoietic stem cell transplantation (HSCT) units (7.3%). Antifungals were used for prophylaxis in 147 patients (48.8%) and for treatment in 154 patients (50.0%). The antifungal treatment strategy in 154 patients was empirical in 77 (50.0%), diagnostic-driven in 29 (18.8%) and targeted in 48 (31.2%). At the point of decision-making for diagnostic-driven antifungal therapy in 29 patients, HRCT had not been performed in 1 patient (3.4%) and galactomannan test results were not available in 12 patients (41.4%). Thirteen patients (8.4%) were receiving eight different antifungal combination therapies. Conclusion: The majority of antifungal drugs for treatment and prophylaxis were prescribed in PHO and HSCT units (42.5%), followed by ICUs. Thus, antifungal stewardship programmes should mainly focus on these patients within the availability of diagnostic tests of each hospital. © 2018 International Society for Chemotherapy of Infection and Cancer
dc.identifier.DOI-ID10.1016/j.jgar.2018.08.007
dc.identifier.issn22137165
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14823
dc.language.isoEnglish
dc.publisherElsevier Ltd
dc.subjectAntifungal Agents
dc.subjectDrug Prescriptions
dc.subjectHospitals, Pediatric
dc.subjectHumans
dc.subjectPrevalence
dc.subjectSurveys and Questionnaires
dc.subjectTertiary Care Centers
dc.subjectTurkey
dc.subjectamphotericin B deoxycholate
dc.subjectamphotericin B lipid complex
dc.subjectantifungal agent
dc.subjectcaspofungin
dc.subjectfluconazole
dc.subjectgalactomannan
dc.subjectmicafungin
dc.subjectposaconazole
dc.subjectvoriconazole
dc.subjectantifungal agent
dc.subjectacute lymphoblastic leukemia
dc.subjectacute myeloid leukemia
dc.subjectantifungal susceptibility
dc.subjectantifungal therapy
dc.subjectArticle
dc.subjectcardiovascular disease
dc.subjectcerebral palsy
dc.subjectchronic respiratory tract disease
dc.subjectcomputer assisted tomography
dc.subjectdrug indication
dc.subjectdrug use
dc.subjectfungus isolation
dc.subjecthematopoietic stem cell transplantation
dc.subjecthospital patient
dc.subjecthuman
dc.subjectimmune deficiency
dc.subjectinvasive aspergillosis
dc.subjectkidney disease
dc.subjectkidney transplantation
dc.subjectliver transplantation
dc.subjectmajor clinical study
dc.subjectmetabolic disorder
dc.subjectmycosis
dc.subjectneurologic disease
dc.subjectprematurity
dc.subjectprescription
dc.subjectpriority journal
dc.subjectTurkey (republic)
dc.subjecthospital
dc.subjectprevalence
dc.subjectquestionnaire
dc.subjecttertiary care center
dc.subjectturkey (bird)
dc.titleAntifungal consumption, indications and selection of antifungal drugs in paediatric tertiary hospitals in Turkey: Results from the first national point prevalence survey
dc.typeArticle

Files

Collections

Scopus Koleksiyonu